UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.725-736

2021

Volltextzugriff (PDF)

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

Cancer research (Chicago, Ill.), 2004-06, Vol.64 (11), p.3761-3766

2004

Volltextzugriff (PDF)

Biomarker analysis (CTC and ctDNA/RNA) of GT0918 (Proxalutamide) new AR blocker in phase I mCRPC patients with dose escalation

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.186-186

2020

Volltextzugriff (PDF)

Abstract 711: Repurposing 2nd generation androgen receptor antagonist Proxalutamide to treat COVID-19

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.711-711

2021

Volltextzugriff (PDF)

Abstract 1265: Discovery of GT19077, a c-Myc/Max protein-protein Interaction (PPI) small molecule inhibitor, and GT19506 a c-Myc PROTAC molecule, for targeting c-Myc-driven blood cancers and small cell lung cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1265-1265

2021

Volltextzugriff (PDF)

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Blood, 2022-11, Vol.140 (Supplement 1), p.483-484

2022

Volltextzugriff (PDF)

Abstract 3297: Discovery and evaluation of GT19870, a GSPT1/Myc molecular glue drug (MGD) with oral bioavailability for targeting c-Myc and n-Myc-addictive blood cancer and solid tumors

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.3297-3297

2024

Volltextzugriff (PDF)

Abstract LB-111: GT19077, a c-Myc/Max protein-protein interaction (PPI) small molecule inhibitor, selectively targets c-Myc-additive B-cell and myeloid malignancies

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.LB-111-LB-111

2020

Volltextzugriff (PDF)

A partially open conformation of an androgen receptor ligand‐binding domain with drug‐resistance mutations

Acta crystallographica. Section F, Structural biology communications, 2023-04, Vol.79 (4), p.95-104

2023

Volltextzugriff (PDF)

Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response

Proceedings of the National Academy of Sciences - PNAS, 2023-07, Vol.120 (30), p.e2221809120

2023

Volltextzugriff (PDF)

Abstract 3861: Proxalutamide (GT0918), a novel androgen receptor (AR) antagonist, targeting resistance mechanisms to AR signaling-directed castration-resistant prostate cancer (CRPC) therapies

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3861-3861

2019

Volltextzugriff (PDF)

Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP-binding cassette (ABC) drug transporters

Biochemical pharmacology, 2004-03, Vol.67 (6), p.1111-1121

2004

Volltextzugriff (PDF)

Abstract 4978: Combination of a clinical stage-hedgehog inhibitor, GT1708, improves Venetoclax-induced apoptosis by down-regulating MCL-1 proteins in AML cells

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4978-4978

2023

Volltextzugriff (PDF)

AML-147 C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill In Vitro and In Vivo in Acute Myeloid Leukemia and Lymphomas

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S218

2022

Volltextzugriff (PDF)

Poster: AML-147 C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill In Vitro and In Vivo in Acute Myeloid Leukemia and Lymphomas

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S127

2022

Volltextzugriff (PDF)

Abstract A03: Discovery and evaluation of GT19630, a c-Myc/n-Myc degrader, for targeting c-Myc-driven B-cell malignancies, acute myeloid leukemia (AML) and n-Myc driven cancers

Blood cancer discovery, 2022-09, Vol.3 (5_Supplement), p.A03-A03

2022

Volltextzugriff (PDF)

Identification and Characterization of the Canine Multidrug Resistance-associated Protein

Molecular cancer therapeutics, 2002-12, Vol.1 (14), p.1335

2002

Volltextzugriff (PDF)

Abstract 5274: Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5274-5274

2022

Volltextzugriff (PDF)

Abstract A31: C-MYC Targeting by Degradation: Novel Dual c-MYC/GSPT1 Degrader GT19715 Induces TP53-independent Cell Death in MYC-amplified Acute Myeloid Leukemia and Lymphomas

Blood cancer discovery, 2023-05, Vol.4 (3_Supplement), p.A31-A31

2023

Volltextzugriff (PDF)

Abstract 5479: Discovery and evaluation of GT19630, a c-Myc/GSPT1 cereblon E3 ligase modulator (CELMoD), for targeting Myc-driven blood cancers and small cell lung cancers (SCLC)

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5479-5479

2022

Volltextzugriff (PDF)

Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.519-519

2017

Volltextzugriff (PDF)

Abstract 2820: LY2784544, a small molecule JAK2 inhibitor, induces apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2820-2820

2011

Volltextzugriff (PDF)

Efficacy of LY2784544, a Small Molecule Inhibitor Selective for Mutant JAK2 Kinase, In JAK2 V617F-Induced Hematologic Malignancy Models

Blood, 2010-11, Vol.116 (21), p.4087-4087

2010

Volltextzugriff (PDF)

The gene encoding vacuolar H +-ATPase subunit C is overexpressed in multidrug resistant HL60 cells

Biochemical and biophysical research communications, 1992-01, Vol.182 (2), p.675-681

1992

Volltextzugriff (PDF)

LY2784544, a Novel JAK2 Inhibitor, Decreases In Vitro Growth of Hematopoietic Human Progenitors From JAK2 V617F Positive Polycythemia Vera Patients

Blood, 2010-11, Vol.116 (21), p.5054-5054

2010

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Englisch
(87)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(23)
Humans
(20)
Physical Sciences
(16)
Technology
(16)
Animals
(11)
Materials Science
(10)
Biological And Medical Sciences
(8)
Medical Sciences
(7)
Chemistry
(6)
Materials Science, Multidisciplinary
(6)
Mice
(6)
Oncology
(6)
Biochemistry & Molecular Biology
(5)
Clinical Trials
(5)
Engineering
(5)
Genes
(5)
Pharmacology. Drug Treatments
(5)
Polymer Science
(5)
Male
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

Biomarker analysis (CTC and ctDNA/RNA) of GT0918 (Proxalutamide) new AR blocker in phase I mCRPC patients with dose escalation

Abstract 711: Repurposing 2nd generation androgen receptor antagonist Proxalutamide to treat COVID-19

Abstract 1265: Discovery of GT19077, a c-Myc/Max protein-protein Interaction (PPI) small molecule inhibitor, and GT19506 a c-Myc PROTAC molecule, for targeting c-Myc-driven blood cancers and small cell lung cancers

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Abstract 3297: Discovery and evaluation of GT19870, a GSPT1/Myc molecular glue drug (MGD) with oral bioavailability for targeting c-Myc and n-Myc-addictive blood cancer and solid tumors

Abstract LB-111: GT19077, a c-Myc/Max protein-protein interaction (PPI) small molecule inhibitor, selectively targets c-Myc-additive B-cell and myeloid malignancies

A partially open conformation of an androgen receptor ligand‐binding domain with drug‐resistance mutations

Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response

Abstract 3861: Proxalutamide (GT0918), a novel androgen receptor (AR) antagonist, targeting resistance mechanisms to AR signaling-directed castration-resistant prostate cancer (CRPC) therapies

Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP-binding cassette (ABC) drug transporters

Abstract 4978: Combination of a clinical stage-hedgehog inhibitor, GT1708, improves Venetoclax-induced apoptosis by down-regulating MCL-1 proteins in AML cells

AML-147 C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill In Vitro and In Vivo in Acute Myeloid Leukemia and Lymphomas

Poster: AML-147 C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill In Vitro and In Vivo in Acute Myeloid Leukemia and Lymphomas

Abstract A03: Discovery and evaluation of GT19630, a c-Myc/n-Myc degrader, for targeting c-Myc-driven B-cell malignancies, acute myeloid leukemia (AML) and n-Myc driven cancers

Identification and Characterization of the Canine Multidrug Resistance-associated Protein

Abstract 5274: Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients

Abstract A31: C-MYC Targeting by Degradation: Novel Dual c-MYC/GSPT1 Degrader GT19715 Induces TP53-independent Cell Death in MYC-amplified Acute Myeloid Leukemia and Lymphomas

Abstract 5479: Discovery and evaluation of GT19630, a c-Myc/GSPT1 cereblon E3 ligase modulator (CELMoD), for targeting Myc-driven blood cancers and small cell lung cancers (SCLC)

Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models

Abstract 2820: LY2784544, a small molecule JAK2 inhibitor, induces apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway

Efficacy of LY2784544, a Small Molecule Inhibitor Selective for Mutant JAK2 Kinase, In JAK2 V617F-Induced Hematologic Malignancy Models

The gene encoding vacuolar H +-ATPase subunit C is overexpressed in multidrug resistant HL60 cells

LY2784544, a Novel JAK2 Inhibitor, Decreases In Vitro Growth of Hematopoietic Human Progenitors From JAK2 V617F Positive Polycythemia Vera Patients

Suchergebnisse filtern